Ra Capital Management, L.P. bought $4.6M of Artiva Biotherapeutics (ARTV)
Executed Jun 12, disclosed Jun 16, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Jun 16), the stock returned -1.1% (delay-adjusted); from the execution session (Jun 12), +8.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
Ra Capital Management, L.P. (Director) filed 30 Form 4 reports as a reporting entity in the trailing twelve months (23 purchases, 7 sales, 1 filed past the two-business-day deadline), most often in Artiva Biotherapeutics, Inc. (ARTV). Across 23 priced purchase filings, the average 21-session return was +14.9% from execution and +14.0% from disclosure (delay-adjusted; derived). The largest single filing was $423.8M of PBLS (21,188,750 sh across 2 lots, as filed), executed Jun 11.
Healthcare · Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for pa…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→45,768 sh across 2 lots
Exec Jul 29
Filed Jul 31 · 5:13 PM ET ARTVPURCHASE Artiva Biotherapeutics, Inc. $413K
41,319 sh × $9.99
Exec Jul 24
Filed Jul 28 · 5:24 PM ET ARTVPURCHASE Artiva Biotherapeutics, Inc. $2.6M
264,586 sh across 3 lots
Exec Jul 21
Filed Jul 23 · 9:22 PM ET ARTVPURCHASE Artiva Biotherapeutics, Inc. $1.4M
152,472 sh × $8.93
Exec Jul 16
Filed Jul 20 · 6:08 PM ET ARTVPURCHASE Artiva Biotherapeutics, Inc. $135K
15,102 sh × $8.97
Exec Jul 10
Filed Jul 14 · 7:00 PM ET ARTVPURCHASE Artiva Biotherapeutics, Inc. $275K
31,000 sh × $8.88
Exec Jun 25
Filed Jun 29 · 4:20 PM ET ARTVPURCHASE Artiva Biotherapeutics, Inc. $7.6M
1,027,619 sh across 2 lots
Exec Jun 9
Filed Jun 11 · 7:36 PM ET ARTVPURCHASE Artiva Biotherapeutics, Inc. $75.0M
6,510,416 sh × $11.52
Exec May 11
Filed May 13 · 5:45 PM ET